Figure 5.

The antitumour effects of the RB, RB-based mDC vaccine, and RB-iDC vaccine treatments. (a) LLC tumours were grown to approximately 1300 mm³ in the groups, with 5 animals per condition. The graphs describe the tumour growth kinetics of the control animals treated with PBS and the animals receiving the three designated treatments, as indicated by the label in the upper right-hand corner of each graph. All animals received RB by intralesional injection; the mice of the RB-based mDC vaccine-treated group received 1 × 10⁶ bone marrow-derived mature DCs pulsed with RB-treated LLC lysis, and the RB-iDC vaccine-treated group underwent RB injection and then received 1 × 10⁶ bone marrow-derived iDCs 10 min later by intralesional injection. Each group received only one treatment. All animals received RB, the RB-based mDC vaccine, or the RB-iDC vaccine on day 0. (b) Mouse survival is shown as a Kaplan–Meier curve (n = 6/group). Significant differences in survival were observed between the RB-iDC vaccine group and the other three groups. (c) The tumours were removed from all the mice of the four groups and photographed. (d) LLC tumour weight comparisons among the four groups were performed on day 30 after the tumour challenge. (e) Representative lungs from the treated mice are shown. (f) Dots represent the mean number ± SD of lung metastasis lesions. ND: not detected. The data represent three independent experiments. Significance between samples was evaluated by one-way ANOVA (ns: not statistically significant, ^∗P < 0.05, ^∗∗P < 0.01, ^∗∗∗P < 0.001, ^∗∗∗∗P < 0.0001).